Skip to content

JARESTO 20 chewable tablets

by PHARMA LINE Srl

Ref PEESLORI0002Model TABLETS

JARESTO 20 chewable tablets (PEESLORI0002) is a Class III device made by PHARMA LINE Srl, registered in EUDAMED on 28 May 2026 (Basic UDI-DI 805826596FT007MDRTABLET9E), active as of 7 Nov 2026.

Active European Union

CE MDR

Valid until

22 Apr 2031

CE MDR certificate

FDA recalls

Not applicable

No FDA record for this device

Documents

1 certificate

Certifier ITALCERT SRL

Trust

Unverified

Source EUDAMED, synced 7 Nov 2026.

Regulatory status

as of registry sync 7 Nov 2026

RegionAuthorizationNumberDateStatus
European UnionCE/MDR Number805826596FT007MDRTABLET9E Basic UDI-DI 08058265962764UDI-DIDate28 May 2026RegisteredStatusActive

Official records

  • EUDAMED public site Basic UDI-DI 805826596FT007MDRTABLET9E — open Devices and search for it

Certificates

1 certificate · EUDAMED

EUDAMED certificates (1)
  • 095-00-00-MDR Active

    Technical documentation EU MDR

    Certifier
    ITALCERT SRL 0426
    Issued
    23 Apr 2026
    Expires
    22 Apr 2031

Coverage

1 jurisdiction

SwedenFinlandLatviaEstoniaDenmarkLithuaniaIrelandNetherlandsGermanyPolandFranceBelgiumLuxembourgCzech RepublicSlovakiaAustriaHungaryRomaniaSloveniaBulgariaPortugalSpainItalyCroatiaGreeceMaltaCyprus
  • Active
  • Expiring
  • Withdrawn
  • Listed
  • Not covered

European Union — CE/MDR Active

Specification

EUDAMED

Device name
Leniref Tablets
Model / reference
TABLETS, PEESLORI0002
Primary DI / UDI-DI
08058265962764
Basic UDI-DI
805826596FT007MDRTABLET9E
EMDN code
G0401 Orally administered devices for the therapy of gastro-intestinal disorders
Device class
Class III
EU registration type
Standard device
EU market of registration
Romania

Manufacturer details

EUDAMED SRN
IT-MF-000032122

Similar devices in this category

Other devices filed under ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS.

Other devices from PHARMA LINE Srl

See all devices from PHARMA LINE Srl →

Properties

Other properties (14, all answered No)